We are thrilled to announce that Converge Bio has launched a collaboration with Compugen, a world-renowned leader in computational target discovery.

Our LLM-based technology will support Compugen's pioneering predictive discovery efforts in identifying novel immuno-oncology drug targets.
As Eran Ophir, Ph.D., Chief Scientific Officer of Compugen said:

"We are delighted to be collaborating with the strong team of experts at Converge Bio to harness their large language models (LLMs) as part of our efforts to accelerate the discovery of novel Immuno Oncology drug targets at Compugen.”

This collaboration marks a significant step forward in realizing our mission at Converge Bio of helping accelerate the discovery of better medications by empowering biotech and pharma companies with the transformative capabilities of LLM-based solutions.

See this post on LinkedIn >